Program Description:
Cardiorenal-metabolic (CRM) syndrome is defined by a multidirectional relationship between the metabolic, cardiovascular, and renal systems, where dysfunction in one organ precipitates and accelerates damage in the others. This multimorbidity is becoming increasingly prevalent in the United States, with more than 90% of individuals with type 2 diabetes having at least one other CRM comorbidity. For managed care pharmacists, the burden of overlapping CRM conditions has contributed to increased annual health care resource utilization and costs. Despite sodium–glucose cotransporter-2 (SGLT2) inhibitors being recognized as foundational therapy for heart failure (HF) and chronic kidney disease (CKD) regardless of diabetes status, restrictive utilization management including step-therapy requirements and prior authorization challenges can contribute to clinical inertia and delay access to these therapies. This activity equips managed care professionals and pharmacists to move beyond reactive management of CRM conditions by translating clinical trial data and real-world evidence into actionable value-based strategies. Participants will gain a cohesive understanding of the CRM disease continuum and the central role of SGLT2 inhibitors as foundational therapy in alignment with multisociety guidelines. Presenters will also guide participants through strategies to develop evidence-informed formularies and approaches to implement innovative outcomes-based agreements keyed to HF hospitalizations or CKD progression to responsibly improve patient outcomes while managing the long-term costs associated with CRM disease.
Target audience: Managed Care Pharmacist
Type of activity: Application
Release date: June 25, 2026
Expiration date: August 25, 2026
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational
Objectives:
At the completion of this activity, participants will be able to:
- Determine the shared pathophysiologic mechanisms, disease progression, and economic impact of cardiorenal-metabolic (CRM) conditions on earlier risk identification and opportunities for coordinated management
- Interpret clinical trial data, guideline recommendations, and comparative evidence related to sodium glucose co-transporter 2 (SGLT2) inhibitors across the CRM continuum to inform patient-centered care strategies
- Construct evidence-informed formulary and benefit design approaches that leverage real-world evidence, cost-effectiveness data, and outcomes-based frameworks to enhance patient access, support individualized treatment decisions, improve adherence, and align total cost of care with the demonstrated value of SGLT2 inhibitors